SEARCH
Home
News
Fortune 500
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Great Place to Work
Tech
AI
Innovation
Cybersecurity
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Success
Future of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Analytics
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Home
News
FORTUNE 500
FORTUNE 500
FORTUNE SEA 500
Fortune 500 Europe
Fortune Global 500
Fortune China 500
Great Place to Work
Tech
Tech
AI
Innovation
Cybersecurity
Finance
Finance
Personal Finance
Real Estate
Economy
Banking
Investing
Crypto
Leadership
Leadership
Success
Future of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Rankings
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Asia
Europe
Analytics
home
home
AstraZeneca
AstraZeneca
Page 2 of 13
Retail
AstraZeneca encounters a surge in shares as profits exceed expectations, buoyed by demand for cancer drugs
By
Ashleigh Furlong
and
Bloomberg
April 25, 2024
Success
Major investors say AstraZeneca boss is ‘massively underpaid’ on $21.5 million salary, despite earning more than double Novo Nordisk’s CEO
By
Ryan Hogg
April 10, 2024
Finance
Meet Europe’s answer to the ‘Magnificent 7’—the high-flying ‘Granolas’ that Goldman Sachs is betting will prosper in the continent’s flatlining economy
By
Ryan Hogg
March 3, 2024
Health
Nasal version of the Oxford/AstraZeneca COVID vaccine fails in U.K. trial
By
Sophie Mellor
October 11, 2022
Health
Top AstraZeneca heart drug Farxiga sees potential to reach more patients
By
Bloomberg
August 27, 2022
Health
The most innovative and inventive drug companies of 2022 set the foundation for success before the pandemic
By
Sy Mukherjee
and
IDEA Pharma
April 20, 2022
Health
New drug that prevents you from catching COVID-19 gets green light in Europe — but it’s been in the U.S. for months and hardly anyone knows about it
By
Sophie Mellor
March 29, 2022
Finance
Omicron is upping booster jab demand. So why are COVID vaccine makers’ shares tanking?
By
Jeremy Kahn
December 29, 2021
Health
Moderna hit by shareholders who want to know why its COVID-19 vaccine is so expensive and unavailable in poorer countries
By
David Meyer
December 27, 2021
Health
AstraZeneca finds its COVID booster delivers adequate protection against Omicron
By
Suzi Ring
and
Bloomberg
December 23, 2021
Health
AstraZeneca COVID-19 vaccine’s protection against severe illness fades quickly, study finds
By
Jeremy Kahn
December 21, 2021
Health
EU bulks up its arsenal against Omicron with approval of Novavax vaccine. Investors dump shares
By
Christiaan Hetzner
December 20, 2021
Health
J&J, Sputnik, and Sinopharm vaccines found to be largely ineffective in fighting Omicron: study
By
Bloomberg
December 17, 2021
International
Omicron is making scientists redefine what it means to be ‘fully vaccinated’ against COVID
By
Sophie Mellor
December 13, 2021
Health
Global drugmakers could roll out Omicron-adapted COVID vaccines in 100 days
By
Yvonne Lau
November 29, 2021
Most Popular
Success
Gen Z is reviving this boring job that millennials and boomers abandoned—and it's helping them land six-figure careers...
By
Preston Fore
Economy
Markets sold off after Powell said six words investors don’t want to hear: ‘Equity prices are fairly highly valued’
By
Jim Edwards
North America
'The frustration is overwhelming': Soybean farmers feel betrayed as Argentina blows a hole in rural America’s $47...
By
Sasha Rogelberg